Recent crises have highlighted the critical need for Europe to secure and strengthen its position as leader in medical innovation. As the European Commission works on the review of the Pharmaceutical Regulation, we need to ensure Europe has the right environment to bring the next generation of treatments to patients. The challenge for the coming decades is not if medical innovation will happen but where it will happen.
This article is part of a series explaining that where innovation happens matters for patients, health care systems, the research community, jobs and the economy.
Now is the time to rethink Alzheimer’s disease to improve Alzheimer’s disease care pathway and the lives of people living... Read more
Innovative Clinical Trials
"Patients with unmet needs are longing for innovative treatments to be approved. Especially rare disease patients, where only 5-6% have approved treatments, need a new strategy to speed up research and provide new opportunities to access innovative drugs. Complex clinical trials can be the change that patients want to see". Claas Röhl, chairman of NF Patients United
During the COVID-19 pandemic, pharmaceutical companies and researchers around the world raced to develop a vaccine.
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.